Saver Study
Statins for Venous Event Reduction in Patients With Venous Thromboembolism
Why are we doing this study
The goal of this study is to see whether, rosuvastatin, a drug that treats high cholesterol, can reduce the risk of recurrent Venous Thromboembolism (VTE) in patients who have already had a Deep Vein Thrombosis (DVT) and/or Pulmonary Embolism (PE), even in patients that don’t necessarily have high cholesterol.
Who is eligible
Patient diagnosed with a blood clot, either in the deep veins of the leg or in the lungs, in the last 30 days.
What is the study treatment plan
Participants will be randomized (assigned by chance) to one of two groups:
- Patients who will take 20 mg of rosuvastatin (Treatment group)
- Patients who will not be given rosuvastatin and proceed with usual care (Control group)
What is involved if I participate in the study
The study will last in average of 3.5 years with a minimum of 6 months and maximum 5 years.
- Screening visit
- Randomization visit
- Telephone follow-up (3, 6, 18, 30, 42, 54 months)
- In-person visit (1, 2, 3, 4, 5 years)
SAVER Study Coordinator
Crystal Sequeira
TEL: 514-340-8222 ext. 21535
Elena Shulikovsky
TEL: 514-340-8222 ext. 23703
